Info

🌱 來自: Antibody Drug Conjugates

Tagraxofusp

• Mechanism: Recombinant IL-3-diphtheria toxin fusion protein; internalization releases truncated diphtheria toxin, producing protein synthesis inhibition & cell death
• Approved indication: Blastic plasmacytoid dendritic cell neoplasm
• Dosing: 12 mcg/kg IV d 1-5 of 21-d cycles; do not dose after cycle d 10 if doses delayed for toxicity; hold if AST &/or AST >5× ULN, &/or if creatinine >1.8 mg/dL or creatinine clearance <60 mL/min; additional hold criteria in package insert
• PK/PD: T1/2 0.7 h
• AEs: Capillary leak syndrome (BBW), hypersensitivity rxns, transaminitis, myelosuppression (20% febrile neutropenia), hyperglycemia, low vomiting risk
• DDI: No DDI studies conducted
• Clinical pearls:
  • Manufacturer-recommended monitoring & management of capillary leak,
  • including predose parameters for administration,
  • available; first cycle must be inpt;
  • premedicate each dose w/
    • H1RA,
    • H2RA,
    • acetaminophen,
    • & corticosteroid